

Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine

Information for the public

Published: 1 November 2023

www.nice.org.uk

Cabozantinib (Cabometyx) is not normally available on the NHS for treating advanced differentiated thyroid cancer in adults when:

- the cancer has got worse after systemic treatment (treatments that work throughout the whole body), and
- radioactive iodine is unsuitable, or the cancer does not respond to it.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS webpage on thyroid cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Butterfly Thyroid Cancer Trust](#), 07399 564463
- [AMEND](#), info@amend.org.uk
- [British Thyroid Foundation](#), 01423 810093
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5515-2